Human Herpesvirus 6 Infection in Patients With Exanthema After Allogeneic Bone Marrow Transplantation

Cleach, Laurence Le; Joberty, Cathy; Fillet, Anne Marie; Sutton, Laurent; Cordonnier, Catherine; Françès, Camille; Agut, Henri; Chosidow, Olivier

doi:10.1001/archderm.134.6.759

Cited by 16 publications

(13 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HHV-6 was recently recognized as an opportunistic pathogen in transplant recipients. In some studies, HHV-6 has been associated with fever and rash resembling acute graft-versus-host disease (GVHD) [4][5][6][7][8][9][10][11], as well as interstitial pneumonitis [12,13], encephalitis [14], cytomegalovirus (CMV) disease [15], and bone marrow suppression [16][17][18][19] after receiving a bone marrow transplant (BMT). However, several large case analyses found no statistical relationship between HHV-6 infection and such clinical events [6,15,17].…”

mentioning

confidence: 99%

Human Herpesvirus 6 Viremia in Bone Marrow Transplant Recipients: Clinical Features and Risk Factors

Yoshikawa¹,

Asano²,

Ihira³

et al. 2002

J INFECT DIS

161

125

View full text Add to dashboard Cite

Human herpesvirus 6 (HHV-6) infection was studied in 82 bone marrow transplant (BMT) recipients (72 allogeneic, 10 autologous). All recipients and 30 donors were seropositive for HHV-6 antibody at the time of bone marrow transplantation. Thirty-one recipients (37.8%) had HHV-6 viremia 2-4 weeks after transplantation. The incidence of HHV-6 viremia was significantly higher among allogeneic BMT recipients than in autologous BMT recipients (P=.011). Therefore, the following analyses of allogeneic BMT recipients were carried out (n=72). Geometric mean antibody titers (log(10)) were significantly higher in recipients without viremia than in those with viremia (1.84+/-0.39 vs. 1.61+/-0.42; P=.022). Logistic regression analysis demonstrated that leukemia or lymphoma is an independent risk factor (P=.031) for HHV-6 viremia. Rash occurring within 1 month after transplantation was observed in 17 (54.8%) of 31 recipients with HHV-6 viremia but in only 8 (19.5%) of 41 recipients without HHV-6 viremia (P=.001).

show abstract

mentioning

confidence: 99%

Human Herpesvirus 6 Viremia in Bone Marrow Transplant Recipients: Clinical Features and Risk Factors

Yoshikawa¹,

Asano²,

Ihira³

et al. 2002

J INFECT DIS

161

125

View full text Add to dashboard Cite

show abstract

“…HHV-6 has recently been recognized as an opportunistic pathogen in transplant recipients. It has been demonstrated that HHV-6 is associated with fever and skin rash resembling acute graft-versus-host disease (GVHD), [4][5][6][7][8][9][10] interstitial pneumonitis, 11,12 encephalitis, 13 and bone marrow suppression 14 after bone marrow transplantation (BMT).…”

mentioning

confidence: 99%

“…Some studies have demonstrated that HHV-6 is a risk factor in causing acute GVHD, 4-10 and others did not support a positive association between HHV-6 and acute GVHD. 15,16 To clarify the issue, two institutes have attempted to detect the virus genome in skin tissues obtained from recipients, 7,8 and have suggested that HHV-6 plays an important role in the development of acute GVHD or skin rash after allogeneic BMT. Most of the previous studies in terms of HHV-6 infection after BMT employed polymerase chain reaction (PCR) analysis to monitor virus activity.…”

mentioning

confidence: 99%

Correlation between HHV-6 infection and skin rash after allogeneic bone marrow transplantation

Yoshikawa

Ihira

Ohashi

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:We investigated whether a causal relationship exists between human herpesvirus 6 (HHV-6) and skin rash resembling acute graft-versus-host disease (GVHD) following bone marrow transplantation (BMT). Isolation of HHV-6 was used to monitor active HHV-6 infection in this study. We analyzed 25 episodes of skin rash in 22 recipients. All recipients were seropositive for HHV-6 before BMT. The onset of skin rash started prior to 30 days post transplantation (group A) in 15 of 25 cases, but after that (group B) in the remaining 10 cases. Twenty-five skin tissue samples were obtained from 22 recipients. The HHV-6 genome was detected in four of 15 skin samples from group A, but not detected in those from group B. HHV-6 was isolated from 11 of 22 recipients around 2 to 3 weeks after BMT (range 14 to 28 days after BMT). HHV-6 was isolated at a time between 10 days before and after the onset of skin rash (skin rash-related viremia) in nine cases in group A. Meanwhile, no skin rash-related viremia was observed in group B. Of the four recipients with positive detection of HHV-6 genome in their skin tissue (group A), two had HHV-6 viremia at the same time. The association between the timing of HHV-6 infection and the onset of skin rash was analyzed statistically. HHV-6 viremia (skin rash-related viremia) was found in nine of 15 (60%) cases in group A, compared with none of 10 (0%) cases in group B. This difference was statistically significant (P = 0.008). Moreover, HHV-6 infection (skin rash-related viremia and/or positive detection of HHV-6 DNA in skin tissue) was demonstrated in 11 of 15 (73.3%) cases in group A, compared with none of 10 (0%) cases in group B (P = 0.001). Thus, this study suggests that HHV-6 may be involved in the development of skin rash in the first month after allogeneic BMT. Bone Marrow Transplantation (2001) 28, 77-81.

show abstract

“…31,32 Several risk factors have been identified for HHV-6 reactivation after HSCT. These include younger age, treatment with steroid, low titers of anti-HHV-6 IgG before HSCT and development of GVHD.…”

Section: Discussionmentioning

confidence: 99%

Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT

Ishiyama

Katagiri

Hoshino

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Human Herpesvirus 6 Infection in Patients With Exanthema After Allogeneic Bone Marrow Transplantation

Cited by 16 publications

References 4 publications

Human Herpesvirus 6 Viremia in Bone Marrow Transplant Recipients: Clinical Features and Risk Factors

Human Herpesvirus 6 Viremia in Bone Marrow Transplant Recipients: Clinical Features and Risk Factors

Correlation between HHV-6 infection and skin rash after allogeneic bone marrow transplantation

Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT

Contact Info

Product

Resources

About